Survival Following Edge-to-Edge Transcatheter Mitral Valve Repair in Patients With Cardiogenic Shock: A Nationwide Analysis.

Gilbert H. L. Tang,Rodrigo Estevez‐Loureiro,Yang Yu,Julie B. Prillinger,Syed Zaid,Mitchell A. Psotka

DOI: https://doi.org/10.1161/jaha.120.019882

IF: 6.106

2021-04-07

Journal of the American Heart Association

Abstract:Background Edge‐to‐edge transcatheter mitral valve repair as salvage therapy in high surgical risk patients with severe mitral regurgitation presenting with cardiogenic shock (CS) has been described in small case series, but large clinical results have not been reported. This study aimed to evaluate outcomes of transcatheter mitral valve repair with MitraClip in patients with mitral regurgitation and CS using a large national database. Methods and Results From January 2014 to March 2019, we identified hospitalizations for CS in patients with mitral valve disease using data from Centers for Medicare and Medicaid Services. Those with a prior surgical or percutaneous mitral valve intervention were excluded. We compared survival between patients who underwent MitraClip during the index hospitalization and those who did not using propensity‐matched analysis. The analysis included 38 166 patients (mean age, 71±11 years, 41.6% women) of whom 622 (1.6%) underwent MitraClip. MitraClip was increasingly used during CS hospitalizations over the study period ( P <0.001). After matching, patients receiving MitraClip had significantly lower in‐hospital mortality (odds ratio, 0.6; 95% CI, 0.47–0.77; P <0.001) and 1‐year mortality (hazard ratio, 0.76; 95% CI, 0.65–0.88; P <0.001) compared with those without MitraClip. The survival benefit associated with MitraClip was consistent across subgroups of interest, with the exception of patients requiring acute mechanical circulatory support or hemodialysis at index. Conclusions In patients with mitral regurgitation presenting with CS, use of MitraClip is increasing and associated with greater in‐hospital and 1‐year survival. Further studies are warranted to optimize patient selection and procedure timing for those receiving MitraClip as a treatment option in CS. Nonstandard Abbreviations and Acronyms CCS Clinical Classification Software CS cardiogenic shock MCS mechanical circulatory support MR mitral regurgitation TMVr transcatheter mitral valve repair Clinical Perspective What Is New? This study reports clinical outcomes for a large nationwide cohort of patients who underwent transcatheter mitral valve repair with MitraClip in the setting of cardiogenic shock. Over the study period from 2014 through early 2019, the use of transcatheter mitral valve repair during cardiogenic shock hospitalizations increased significantly. In a matched‐cohort analysis of 1192 patients, MitraClip therapy was associated with higher in‐hospital and 1‐year survival in patients with mitral regurgitation and cardiogenic shock. What Are the Clinical Implications? MitraClip may be considered as a therapeutic option for some critically ill patients. Clinical studies on the patient and procedural characteristics associated with MitraClip in the setting of cardiogenic shock could further improve outcomes by optimizing procedural timing and patient selection. Management of severe mitral regurgitation (MR) in patients presenting with cardiogenic shock (CS) remains challenging because of complications including respiratory failure from acute pulmonary edema and multiorgan dysfunction. 1 , 2 Inotropic and mechanical circulatory support may be lifesaving, but MR and shock may persist without definitive treatment. Surgical mitral valve repair or replacement in these critically ill patients carries significant mortality and morbidities. 3 The typical pathology of severe MR in CS consists of either a flail leaflet segment secondary to ruptured chordae or papillary muscle because of acute myocardial infarction, or progressive decompensation with chronic MR from leaflet restriction because of ischemic or non‐ischemic cardiomyopathy. Given the high surgical risk in this patient population, edge‐to‐edge transcatheter mitral valve repair (TMVr) has been attempted as salvage therap -Abstract Truncated-

cardiac & cardiovascular systems